Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Down 67.6% in March

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 868,800 shares, a decrease of 67.6% from the February 28th total of 2,680,000 shares. Approximately 17.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 5,360,000 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Apollon Wealth Management LLC bought a new stake in shares of Quoin Pharmaceuticals in the 4th quarter worth about $52,000. Boothbay Fund Management LLC purchased a new stake in shares of Quoin Pharmaceuticals in the fourth quarter worth approximately $53,000. Renaissance Technologies LLC lifted its position in shares of Quoin Pharmaceuticals by 244.1% during the fourth quarter. Renaissance Technologies LLC now owns 133,122 shares of the company’s stock worth $87,000 after purchasing an additional 94,431 shares during the last quarter. Finally, Altium Capital Management LLC bought a new stake in Quoin Pharmaceuticals during the 4th quarter valued at about $184,000. 8.63% of the stock is owned by hedge funds and other institutional investors.

Quoin Pharmaceuticals Trading Down 11.6 %

Shares of NASDAQ:QNRX traded down $0.03 during trading on Friday, reaching $0.25. The company’s stock had a trading volume of 165,680 shares, compared to its average volume of 2,275,544. The stock has a market capitalization of $1.27 million, a PE ratio of -0.06 and a beta of 1.82. Quoin Pharmaceuticals has a 12 month low of $0.24 and a 12 month high of $1.57. The firm’s 50 day simple moving average is $0.33 and its two-hundred day simple moving average is $0.53.

Quoin Pharmaceuticals (NASDAQ:QNRX) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.15. Research analysts anticipate that Quoin Pharmaceuticals will post -2.05 EPS for the current fiscal year.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.